Collaborative Research Agreement (CRA)

A Collaborative Research Agreement (CRA) is the contract that establishes and governs a joint research project between two or more independent institutions or companies. It is the most general-purpose instrument in a research administrator’s contracting toolkit for multi-party research: rather than transferring one specific thing (a material, a dataset, funding), it sets the overall terms of the collaboration itself — who contributes what, who owns what comes out of it, and who can publish what and when.

Despite the acronym-adjacent name, a general CRA is a genuinely different instrument from a CRADA (Cooperative Research and Development Agreement), which is a specific U.S. federal statutory mechanism authorized under 15 U.S.C. 3710a for a federal laboratory (NIH intramural, a DOE national lab, a military lab, etc.) to jointly perform R&D with a non-federal partner. A CRA, by contrast, has no single statutory basis, is not restricted to federal-lab participants, and is the instrument two universities, a university and a company, a hospital and a research institute, or any combination of non-federal-lab entities use to formalize a joint project. The confusion is understandable given the similar names, but the two should not be used interchangeably: a federal laboratory partnering with industry needs a CRADA (or, in some agencies, a different statutory vehicle); a university partnering with another university or a company on a jointly-performed research project needs a CRA.

What a CRA typically covers

Terms vary by institution and by the specifics of the collaboration, but a CRA generally addresses:

• Scope of work — the research question(s), each party’s role, and the project timeline.
• Contributions — what each party brings: personnel time, lab facilities and equipment, funding, existing (background) IP, or data.
• Intellectual property allocation — how background IP each party brings into the collaboration stays separately owned, and how foreground IP (inventions, data, or other outputs created during the collaboration) is owned, licensed, or jointly held between the parties. Where the collaboration is jointly funded (rather than one party sponsoring the other), IP terms are typically negotiated between the parties directly, unlike a Sponsored Research Agreement (SRA), where one party is funding the other to perform defined work and the funding party commonly negotiates a license or option to the results.
• Publication rights — each party’s right to publish results, usually subject to a short review period (commonly on the order of 30-90 days) allowing collaborators to check for inadvertent disclosure of the other party’s confidential information or to file a patent application before public disclosure.
• Confidentiality — obligations covering information exchanged during the collaboration, often for a defined term after the agreement ends.
• Term, termination, and liability — how long the agreement runs, how either party can exit, and standard indemnification/liability allocation.

The ‘umbrella’ relationship to MTA, CDA, and DUA

A defining feature of a CRA is that it is usually the umbrella under which narrower, single-purpose agreements sit for one specific collaboration. Rather than re-negotiating IP, liability, and general terms every time the parties need to exchange one specific thing, the CRA establishes the overall relationship once, and the parties execute shorter, subordinate agreements referencing it for individual exchanges:

• Material Transfer Agreement (MTA) — governs the transfer of a specific biological or physical research material (a cell line, reagent, or compound) from one collaborating party to the other, including permitted use and restrictions on further distribution.
• Confidential Disclosure Agreement (CDA), also commonly called a Non-Disclosure Agreement (NDA) — governs the exchange of confidential information. A CDA is frequently signed before a CRA is finalized, to let the parties discuss a potential collaboration in confidence, and may also be executed for a specific ancillary disclosure once the CRA is in place. See CASRAI’s guide to non-disclosure agreements in research and technology transfer for how these function in practice.
• Data Use Agreement (DUA) — governs the transfer and permitted use of a specific dataset between the parties, including any restrictions (e.g., prohibitions on re-identification for datasets containing human-subjects information).

In practice, a research administrator managing a multi-institutional project will often see one CRA on file for the overall collaboration, with one or more MTAs, CDAs, or DUAs executed underneath it as specific exchanges occur — each referencing the CRA’s general terms (governing law, liability, publication rights) rather than re-stating them, while adding the specific terms particular to that one transfer.

CRA vs. Sponsored Research Agreement (SRA)

A CRA is also distinct from a Sponsored Research Agreement, though the line between the two can blur in practice. An SRA typically describes a one-directional relationship: a sponsor (often industry or a funding agency) pays a research-performing institution to carry out defined work, and the sponsor commonly negotiates rights to the results. A CRA more often describes a relationship where multiple parties jointly perform and jointly fund (or in-kind contribute to) the research, without one party simply paying the other to do the work. Some institutions use ‘collaborative research agreement’ and ‘sponsored research agreement’ as near-synonyms in their own templates, so the actual terms of a given agreement — not its title — determine which pattern it follows.

Example

Two universities agree to jointly develop and validate a new diagnostic assay: University A contributes a patient sample cohort and clinical expertise; University B contributes an analytical platform and bioinformatics staff time. The parties sign a single CRA covering the joint project, IP allocation for any resulting invention, and publication rights. Partway through the project, University A needs to send de-identified patient samples to University B; the parties execute a subordinate MTA (for the physical samples) and a DUA (for the associated dataset), each referencing the CRA’s governing terms.

Counter-example

A national laboratory operated by a U.S. federal agency partners with a private biotechnology company to co-develop a manufacturing process, with the lab contributing government scientists’ time and existing government-owned IP and the company contributing funding and complementary IP. Because one party is a federal laboratory acting under its statutory authority, this relationship is documented as a CRADA, not a general CRA — the federal-lab party’s participation is governed by the Federal Technology Transfer Act (15 U.S.C. 3710a), which imposes requirements (e.g., on IP licensing and protected CRADA information) that don’t apply to a purely non-federal collaboration.